CITY OF HOPE NATIONAL MEDICAL CTR
- Type
- Teaching hospital
- Where
- Duarte, CA
- Medicare CCN
- 050146
- Received
- $84,132,369 in 1,747 records, 2021 ($41,921,430 general, $42,210,939 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 137 | $41,921,430 |
| 2021 | Research payment | 1,610 | $42,210,939 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,610 | $42,210,939 |
| Royalty or License | 88 | $41,294,682 |
| Consulting Fee | 21 | $345,047 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $118,467 |
| Space rental or facility fees (teaching hospital only) | 16 | $88,000 |
| Grant | 1 | $59,000 |
| Long term medical supply or device loan | 3 | $13,250 |
| Debt forgiveness | 3 | $2,981 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,050,207 | Research payment | In-kind items and services | ZOLINZA Drug, ONCOLOGY | A Phase I Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-cell Lymphoma, Follicular Ly | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,102,095 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II trial of lenvatinib-pembrolizumab maintenance therapy in patients with advanced unresectable pancreatic cancer | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $914,264 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase I study of the addition of MK-3475 pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $600,309 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A PHASE II STUDY OF A P53MVA VACCINE IN COMBINATION WITH PEMBROLIZUMAB IN PLATINUM RESISTANT OVARIAN CANCER | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $350,354 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $345,110 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $323,193 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I Clinical Trial Combining Pembrolizumab and Lenalidomide for the Treatment of Patients with Myelodysplastic Syn | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $316,782 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2 Trial of Neoadjuvant Chemoradiation with Pembrolizumab followed by pembrolizumab with lenvatinib in esophageal | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $230,562 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab Plus Ibrutinib for Treatment of Relapsed or Refractory Peripheral T-cell Lymphomas | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $175,746 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $175,409 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $172,151 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1 Study of Combination Immunotherapy Blinatumomab and Pembrolizumab anti-PD-1,MK-3475 in Subjects with Relapsed, | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $158,933 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $130,619 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $130,480 | Research payment | In-kind items and services | Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $123,852 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $118,122 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II trial of lenvatinib-pembrolizumab maintenance therapy in patients with advanced unresectable pancreatic cancer | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $84,893 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II clinical trial of MK-3475 pembrolizumab in subjects with relapsed or refractory R,R classical Hodgkin Lymphom | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $68,284 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A Coformulated MK-1308,MK-3475 in C | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $57,926 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab MK-3475 monotherapy versus standard chemotherapy in P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $52,313 | Research payment | In-kind items and services | Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $52,120 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $52,120 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $49,532 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671,V941 as a Monotherapy and in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $45,129 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $38,773 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab MK-7684 with Pembrolizumab M | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $37,483 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $35,535 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $32,825 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab MK-7684 with Pembrolizumab M | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $32,576 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671,V941 as a Monotherapy and in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $31,752 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $30,806 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Combining Pembrolizumab and Palliative Radiotherapy in Metastatic Gastroesophageal Cancer to Enhance Anti-Tumor T cell R | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $30,616 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,367 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A Coformulated MK-1308,MK-3475 in C | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $25,708 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II clinical trial of MK-3475 pembrolizumab in subjects with relapsed or refractory R,R classical Hodgkin Lymphom | 2021 |
| 2021-12-31 | SERVIER PHARMACEUTICALS LLC | $25,107 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $24,812 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $20,305 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab MK-3475 plus Chemotherapy XP or FP versus Placebo | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,536 | Research payment | Cash or cash equivalent | Biological, ONCOLOGY | A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $17,257 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $15,152 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $14,915 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,905 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,778 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $13,525 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,275 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $9,702 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $8,548 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,714 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,252 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Subjects with High Risk Non-muscl | 2021 |
| 2021-12-31 | Linvatec Corporation | $4,727 | Long term medical supply or device loan | In-kind items and services | HELIX Device, GENERAL SURGERY | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $4,660 | Research payment | Cash or cash equivalent | CoHHuimMRClinicalMR2021 | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,228 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,760 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab MK-3475 plus Chemotherapy XP or FP versus Placebo | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,779 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $2,228 | Research payment | Cash or cash equivalent | COH2020MRIPR798Chen | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,171 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,833 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $1,650 | Research payment | Cash or cash equivalent | COH2019MRIPR548Chaudhry | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,183 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,115 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pem | 2021 |
| 2021-12-31 | ABBVIE INC. | $927 | Research payment | In-kind items and services | A First In Human Study of the MCL-1 Inhibitor, ABBV-467 | 2021 | |
| 2021-12-31 | KLS-Martin L.P. | $669 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | Merck Sharp & Dohme LLC | $474 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Met | 2021 |
| 2021-12-31 | Medline Industries LP | $434 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $359 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $343 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase III, Multicenter, Randomized Study to Evaluate MK 1308A Co-formulated MK 1308,MK 3475 Versus Chemotherapy as Adj | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $270 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $270 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $270 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $82 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A MK-7684 Vibostolimab with MK-3475 Pembrolizu | 2021 |
| 2021-12-31 | EMD Serono, Inc. | $74 | Research payment | Cash or cash equivalent | Tepmetko Drug, Oncology | A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET | 2021 |
| 2021-12-31 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-31 | Incyte Corporation | $52 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $22 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III Open Label Randomized Study to Assess the Efficacy and Safety of Olaparib Lynparza Versus Enzalutamide or Ab | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01Substudy 1 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combi | 2021 |
| 2021-12-30 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-30 | Incyte Corporation | $52 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-29 | TG Therapeutics, Inc. | $55,576 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Ob | 2021 |
| 2021-12-29 | TG Therapeutics, Inc. | $55,576 | Research payment | Cash or cash equivalent | UKONIQ Drug, Hematology | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Ob | 2021 |
| 2021-12-29 | SEAGEN INC. | $24,610 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-12-29 | RefleXion Medical, Inc. | $10,000 | Research payment | Cash or cash equivalent | REFLEXION MEDICAL RADIOTHERAPY SYSTEM Device, RADIOTHERAPY EQUIPMENT | Research Protocol: A Pragmatic Evaluation of Suitability of BgRT for Liver Metastasis Ablation in a Contemporary Radiati | 2021 |
| 2021-12-29 | SEAGEN INC. | $8,247 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-12-29 | ABBVIE INC. | $1,720 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults | 2021 |
| 2021-12-29 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-28 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-27 | Janssen Research & Development, LLC | $43,196 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Su | 2021 | |
| 2021-12-24 | Janssen Research & Development, LLC | $10,426 | Research payment | Cash or cash equivalent | A Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for | 2021 | |
| 2021-12-23 | Amgen Inc. | $18,839 | Research payment | Cash or cash equivalent | Blincyto Biological, Oncology | Newly diagnosed elderly PH- ALL random. of low intensity chemo with blin versus SOC | 2021 |
| 2021-12-23 | SERVIER PHARMACEUTICALS LLC | $1,485 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-23 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-23 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-22 | PFIZER INC. | $583,929 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2021 |
| 2021-12-22 | PFIZER INC. | $80,425 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2021 |
| 2021-12-22 | PFIZER INC. | $51,446 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2021 |
| 2021-12-22 | Kite Pharma, Inc. | $9,624 | Research payment | Cash or cash equivalent | A Phase 1 Study Evaluating the Safety and Efficacy of HPV-16 E7 T. Cell Receptor Engineered T Cells(KTE-439) in HLA-A*0 | 2021 | |
| 2021-12-22 | PFIZER INC. | $4,922 | Research payment | Cash or cash equivalent | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 | 2021 | |
| 2021-12-22 | MACROGENICS, INC. | $3,285 | Research payment | Cash or cash equivalent | MARGENZA Drug, Oncology | COMBINATION MARGETUXIMAB, INCMGA00012, MGD013, AND CHEMOTHERAPY PHASE 2 3 TRIAL IN HER2 GASTRIC GEJ CANCER MAHOGANY | 2021 |
| 2021-12-22 | Gilead Sciences, Inc. | $3,212 | Research payment | Cash or cash equivalent | A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies | 2021 | |
| 2021-12-22 | Kite Pharma, Inc. | $1,251 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination wit | 2021 |
| 2021-12-22 | Incyte Corporation | $287 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-21 | Genentech, Inc. | $91,172 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE IA IB OPEN LABEL DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XMAB24306 ALO | 2021 |
| 2021-12-21 | ABBVIE INC. | $51,628 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults | 2021 |
| 2021-12-21 | ABBVIE INC. | $6,883 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults | 2021 |
| 2021-12-21 | PUMA BIOTECHNOLOGY, INC. | $3,898 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP | 2021 |
| 2021-12-21 | ABBVIE INC. | $3,441 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults | 2021 |
| 2021-12-21 | ABBVIE INC. | $688 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults | 2021 |
| 2021-12-21 | Eli Lilly and Company | $667 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VAN | 2021 | |
| 2021-12-21 | Incyte Corporation | $345 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-21 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-20 | Bayer Healthcare Pharmaceuticals Inc. | $63,000 | Research payment | Cash or cash equivalent | Xofigo Drug, Oncology | Combination treatment: Radium 223 +ADT+radiation | 2021 |
| 2021-12-20 | Merck Sharp & Dohme LLC | $32,400 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1,2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer | 2021 |
| 2021-12-20 | Janssen Research & Development, LLC | $18,862 | Research payment | Cash or cash equivalent | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cance | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $17,500 | Research payment | Cash or cash equivalent | A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants wi | 2021 | |
| 2021-12-20 | Exelixis Inc. | $9,467 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2021 |
| 2021-12-20 | Janssen Research & Development, LLC | $1,291 | Research payment | Cash or cash equivalent | A Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub | 2021 | |
| 2021-12-20 | Incyte Corporation | $345 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-17 | Genentech, Inc. | $136,845 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | PH IB CEVOSTAMAB IN PATIENTS WITH R R MM | 2021 |
| 2021-12-17 | Aveo Pharmaceuticals, Inc. | $51,331 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Car | 2021 |
| 2021-12-17 | Merck Sharp & Dohme LLC | $43,925 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-17 | Ipsen Bioscience Inc. | $35,964 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Le | 2021 |
| 2021-12-17 | Aveo Pharmaceuticals, Inc. | $31,783 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Car | 2021 |
| 2021-12-17 | Janssen Research & Development, LLC | $7,946 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2021 | |
| 2021-12-17 | Janssen Research & Development, LLC | $7,392 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2021 | |
| 2021-12-17 | Incyte Corporation | $115 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-16 | SEAGEN INC. | $24,743 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-12-16 | SEAGEN INC. | $6,233 | Research payment | In-kind items and services | TUKYSA Drug, Oncology | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-12-16 | Pharmacyclics LLC, an AbbVie Company | $1,754 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2021 |
| 2021-12-16 | Pharmacyclics LLC, an AbbVie Company | $479 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2021 |
| 2021-12-16 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone DRVd Versus Lenalido | 2021 | |
| 2021-12-16 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-16 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-15 | PFIZER INC. | $77,195 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2021 |
| 2021-12-15 | Genentech, Inc. | $19,324 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | PH IB CEVOSTAMAB IN PATIENTS WITH R R MM | 2021 |
| 2021-12-15 | Incyte Corporation | $9,547 | Research payment | Cash or cash equivalent | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Pa | 2021 | |
| 2021-12-15 | Incyte Corporation | $230 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-15 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-14 | Takeda Pharmaceuticals U.S.A., Inc. | $28,858 | Research payment | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | A STUDY TO EVALUATE THE EFFICACY OF BRIGATINIB (AP26113) IN PARTICIPANTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE, | 2021 |
| 2021-12-14 | Takeda Pharmaceuticals U.S.A., Inc. | $6,393 | Research payment | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | A STUDY TO EVALUATE THE EFFICACY OF BRIGATINIB (AP26113) IN PARTICIPANTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE, | 2021 |
| 2021-12-14 | Exelixis Inc. | $3,561 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $3,470 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Genentech, Inc. | $3,200 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-12-14 | Exelixis Inc. | $2,859 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $388 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $329 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $329 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $329 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $311 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $220 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-14 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-14 | Exelixis Inc. | $19 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $19 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $19 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-14 | Exelixis Inc. | $19 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2021 |
| 2021-12-13 | Merck Sharp & Dohme LLC | $481,352 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Phase II trial of lenvatinib-pembrolizumab maintenance therapy in patients with advanced unresectable pancreatic cancer | 2021 |
| 2021-12-13 | ABBVIE INC. | $27,597 | Research payment | Cash or cash equivalent | A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib i | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $14,444 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Open Label Study of the Safety Pharmacokinetics and Pharmacodynamics of JNJ67856633 an Inhibito | 2021 | |
| 2021-12-13 | CSL Behring | $2,384 | Research payment | Cash or cash equivalent | Long-term Follow-up for the Detection of Delayed Adverse Events in Subjects who Participated in a CSL Behring-sponsored | 2021 | |
| 2021-12-13 | SERVIER PHARMACEUTICALS LLC | $1,526 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-13 | Amgen Inc. | $978 | Research payment | In-kind items and services | Blincyto Biological, Oncology | Phase 1b SubQ study in DLBCL. | 2021 |
| 2021-12-13 | Institut de Recherches Servier | $225 | Research payment | In-kind items and services | LONSURF Drug, GASTROENTEROLOGY | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2021 |
| 2021-12-13 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-13 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-11 | Incyte Corporation | $939 | Research payment | Cash or cash equivalent | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-10 | Incyte Corporation | $6,902 | Research payment | Cash or cash equivalent | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-10 | Incyte Corporation | $5,544 | Research payment | Cash or cash equivalent | A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib | 2021 | |
| 2021-12-10 | JAZZ PHARMACEUTICALS INC. | $1,870 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 1B TRIAL OF CPX-351 LOWER INTENSITY THERAPY (LIT) PLUS VENETOCLAX AS FIRST LINE TREATMENT FOR SUBJECTS WITH AML | 2021 |
| 2021-12-10 | Institut de Recherches Servier | $226 | Research payment | In-kind items and services | LONSURF Drug, GASTROENTEROLOGY | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2021 |
| 2021-12-10 | Incyte Corporation | $210 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-10 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-09 | Janssen Research & Development, LLC | $80,526 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Su | 2021 | |
| 2021-12-09 | Genentech, Inc. | $17,500 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-12-09 | Incyte Corporation | $230 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-09 | Institut de Recherches Servier | $225 | Research payment | In-kind items and services | LONSURF Drug, GASTROENTEROLOGY | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2021 |
| 2021-12-09 | Institut de Recherches Servier | $225 | Research payment | In-kind items and services | LONSURF Drug, GASTROENTEROLOGY | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2021 |
| 2021-12-09 | ABBVIE INC. | $172 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Afte | 2021 |
| 2021-12-08 | Genentech, Inc. | $92,985 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L BILIARY TRACT CANCER | 2021 |
| 2021-12-08 | ABBVIE INC. | $38,721 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Phase I multi-site study evaluating the MTD, safety and efficacy of the combination venetoclax, lenalidomide and rituxim | 2021 |
| 2021-12-08 | PFIZER INC. | $12,268 | Research payment | In-kind items and services | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND A | 2021 | |
| 2021-12-08 | PFIZER INC. | $4,497 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITU | 2021 | |
| 2021-12-08 | Amgen Inc. | $1,930 | Research payment | In-kind items and services | Ph1/3 1L Gastric bema+chemo+nivo | 2021 | |
| 2021-12-08 | Incyte Corporation | $172 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-08 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-07 | PFIZER INC. | $916 | Research payment | Cash or cash equivalent | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 | 2021 | |
| 2021-12-07 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-07 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-06 | SANOFI US SERVICES INC. | $28,950 | Research payment | Cash or cash equivalent | Act-IV-combo with pembrolizumab or cetuximab-advanced gastro-intestinal cancers | 2021 | |
| 2021-12-06 | Janssen Research & Development, LLC | $12,664 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-12-06 | Linvatec Corporation | $7,618 | Long term medical supply or device loan | In-kind items and services | LINVATEC VIDEO ACCESSORIES Device, ORTHOPEDIC SURGERY | 2021 | |
| 2021-12-06 | Incyte Corporation | $345 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-06 | Incyte Corporation | $210 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-03 | Janssen Research & Development, LLC | $3,178 | Research payment | Cash or cash equivalent | An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with B | 2021 | |
| 2021-12-03 | E.R. Squibb & Sons, L.L.C. | $1,207 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread t | 2021 |
| 2021-12-03 | Incyte Corporation | $105 | Research payment | In-kind items and services | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2021 | |
| 2021-12-03 | Incyte Corporation | $57 | Research payment | In-kind items and services | GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chron | 2021 | |
| 2021-12-02 | Bayer Healthcare Pharmaceuticals Inc. | $37,500 | Research payment | Cash or cash equivalent | Non-Covered | An open label first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harbo | 2021 |
| 2021-12-02 | Genentech, Inc. | $22,500 | Consulting Fee | Cash or cash equivalent | 2021 |
The latest 200 records of 1,747.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Duarte, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Duarte, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 22,184 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 21,727 | 10,014,009 | 39,538,223 |
| Median age B01002 | 44.9 | 38.2 | 37.9 |
| Under 18 B01001 | 17.5% | 20.6% | 22.0% |
| 65 and over B01001 | 21.6% | 15.2% | 15.7% |
| Households B11001 | 7,515 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 32.5% | 33.4% | 27.0% |
| Median household income B19013 | $105,483 | $90,112 | $99,122 |
| Median family income B19113 | $123,242 | $101,573 | $113,346 |
| Per capita income B19301 | $41,415 | $45,792 | $49,513 |
| Poverty rate B17001 | 8.4% | 13.7% | 12.0% |
| Unemployment rate B23025 | 5.6% | 7.3% | 6.6% |
| Civilian labor force B23025 | 11,818 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.3 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 33.9% | 36.0% | 37.1% |
| Housing units B25001 | 7,832 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 61.0% | 45.9% | 55.9% |
| Renters B25003 | 39.0% | 54.1% | 44.1% |
| Median home value B25077 | $779,400 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,105 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 23.5% | 24.7% | 33.8% |
| Black B03002 | 4.0% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 49.4% | 48.4% | 40.2% |
| Asian B03002 | 17.9% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Duarte, CA.
Comments